Report #2842685

Received May 26, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 40 yrs
State: OH
Recovered: Unknown
Vaccinated: Apr 22, 2025
Onset: Apr 22, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEPAB	HEP A + HEP B (TWINRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	797F9	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Twinrix late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 40-year-old female patient who received HAB (Twinrix) (batch number 797F9, expiry date 30-DEC-2025) for prophylaxis. Previously administered products included Twinrix (1st dose received on 20-MAY-2019 with batch number-95KG9 and expiry date 29-OCT-2020). On 22-APR-2025, the patient received the 2nd dose of Twinrix. On 22-APR-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Twinrix late second dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 20-MAY-2025 The patient received 2nd dose at longer interval than recomeded which led lengthening of vaccination schedule. Registered pharmacist wanted to know if he should restart the series or how much time to wait before giving a third dose of Twinrix after his patient received the first dose. The reporter consented to follow up.